PHARMARON - Shenzhen Xinzhong Kangcheng Investment Partnership (Limited Partnership), a shareholder holding more than 5% of the company's shares, and Shenzhen Xinzhong Kangcheng Investment Partnership (Limited Partnership), a person acting in concert with the company, issued an announcement regarding the changes in shareholdings of shareholders holding more than 55% of the shares, involving a multiple of 11%.
PHARMARON - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Exchange”) and Hong Kong Securities Clearing Company Limited
("Hong Kong Clearing") takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness, and expressly expressly disclaims any liability for any loss arising out of or in reliance upon the whole or any part of the contents of this announcement. Ren.
Pharmaron Beijing Co., Ltd.
Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd. (a joint stock limited company incorporated in the People's Republic of China) (Stock code: 3759)
Overseas regulatory announcement
This announcement is made by Pharmaron Chemicals (Beijing) New Drug Technology Co., Ltd. (the "Company") pursuant to the made under Rule 13.10B of the Rules Governing the Listing of Securities of Limited Company.
The announcement published by the Company on the Shenzhen Stock Exchange website is set out below for reference only.
By order of the board of directors Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd.
Chairman Dr. Lou Pak Leung
People's Republic of China, Beijing July 2, 2026
As at the date of this announcement, the board of directors includes executive directors Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei; employees Representative Director Mr. Li Chengzong; Non-executive Director Ms. Wan Xuan; Independent Non-executive Directors Ms. Li Lihua and Zeng Jin
Professor Feng and Ms. Shen Rong.
Securities code: 300759 Securities abbreviation: Pharmaron Announcement number: 2026-049
Kangkanglong Longhua Chemical ((Beijing)) New New Pharmaceutical Technology Co., Ltd.
Announcement regarding changes in shareholdings of shareholders holding more than 55% of the shares touching an integral multiple of 11%%
Shenzhen Xinzhong Kangcheng Investment Partnership (Limited Partnership), a shareholder holding more than 5% of the company's shares, and its peers
Touching Shenzhen Xinzhong Longcheng Investment Partnership (Limited Partnership) guarantees that the information provided to the company is true
It is true, accurate and complete, and there are no false records, misleading statements or major omissions. The company and all members of the board of directors guarantee that the content of the announcement is consistent with the information provided by the information disclosure obligor.
Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd. (hereinafter referred to as the "Company") recently received
Shenzhen Xinzhong Kangcheng Investment Partnership (Limited Partnership), a shareholder holding more than 5% of the company's shares (hereinafter referred to as "Xinzhong Kangcheng Investment Partnership")
Zhongkangcheng") and its persons acting in concert, Shenzhen Xinzhong Longcheng Investment Partnership (Limited Partnership) (hereinafter referred to as "Letter of Notification of Shareholding Reduction Progress" issued by "Xinzhong Longcheng"). It was learned that Xinzhong Kangcheng and Xinzhong Longcheng were reducing their shareholdings.
Resulting in share changes touching an integral multiple of 1%. The relevant situation is now announced as follows:
- Specific situations where the shareholding ratio touches an integral multiple of 1%
1.Basic basic situation Information disclosure obligor Shenzhen Xinzhong Kangcheng Investment Partnership (Limited Partnership) (1) Xiangjiang Gold, No. 3046, Xinghai Avenue, Nanshan Street, Qianhai Shenzhen-Hong Kong Cooperation Zone, Shenzhen City residence Rong Building 1314-B8 Information disclosure obligor Shenzhen Xinzhong Longcheng Investment Partnership (Limited Partnership) (2) Xiangjiang Gold, No. 3046, Xinghai Avenue, Nanshan Street, Qianhai Shenzhen-Hong Kong Cooperation Zone, Shenzhen City residence Rong Building 1314-B9 Equity change time July 1, 2026
Due to their own financial needs, Xinzhong Kangcheng and Xinzhong Longcheng will Total reduction of holdings in companies from June 16 to July 1, 2026 17,800,000 shares. Among them, Xinzhong Kangcheng traded through centralized bidding. Reduce its holdings of 7,600,000 shares of the company through block transactions
Equity change process 5,000,000 shares; Xinzhong Longcheng reduced its holdings through centralized bidding transactions 5,200,000 shares of the company, reduced 0 shares of the company through block transactions portion. This shareholding reduction is carried out in accordance with the disclosed plan. The shareholding reduction plan The implementation will not have a significant impact on the company's governance structure and sustainable operations. It will not cause any change in the control of the company.
Stock abbreviation Pharmaron Stock Code 300759
Direction of change Up □ Down √ Persons acting in concert Yes √ No □
Is it the largest shareholder or actual controller? Yes□ No√ 2. Changes in equity interests of this subsidiary
Type of shares Number of shares reduced (shares) Change ratio (%)
A shares (Xin Zhongkang 12,600,000 0.69 into) A shares (Xinzhonglong 5,200,000 0.28 into) Total 17,800,000 0.97 Centralized trading through stock exchanges √ The method of this equity change Block trades through stock exchanges √ (multiple choices available) Others □ 3. Before and after this change, investors and their concerted actions have changed the status of the shares with equity interests in the listed company. Shares held before this change. Shares held after this change. Nature of shares Share of total share capital Share of total share capital Number of shares (shares) Number of shares (shares) Proportion Note 1 (%) Proportion Note 1 (%) Shares held by Xinzhong Kangcheng 214,597,333 11.68 201,997,333 10.99 Among them: unlimited sales conditions 214,597,333 11.68 201,997,333 10.99 shares Limited sales conditions 0 0.00 0 0.00 shares Shares held by Xinzhong Longcheng 5,200,000 0.28 0 0.00 Among them: unlimited sales conditions 5,200,000 0.28 0 0.00 shares Limited sales conditions 0 0.00 0 0.00 shares Total 219,797,333 11.96 201,997,333 10.99 4. Performance of commitments, plans, etc.
Yes √ No □ The company disclosed on April 30, 2026 "About shares holding more than 5% of the shares" Pre-disclosure Announcement on the Reduction of Dongfang’s Shareholdings" (Announcement No.: 2026-033), on Under this shareholding reduction plan, from May 27, 2026 to June 15, 2026 Is this change a fulfillment of On June 16, 2026, Xinzhong Longcheng reduced its holdings by a total of 5,516,600 shares. fulfill the commitments made, As of July 1, 2026, Xinzhong Kangcheng and Xinzhong Longcheng have reduced their holdings cumulatively intention, plan 17,800,000 shares. This shareholding reduction plan has not yet been completed. This equity change is consistent with the previously disclosed shareholding reduction plan. Within the scope of the disclosed shareholding reduction plan, there is no violation of the disclosed shareholding reduction plan. plans and related commitments. Does this change exist? Violation of the Securities Act "Public Company Acquisition Management" Laws such as "Administration Measures", Yes□ No√ Administrative regulations, departmental regulations chapters, normative documents and Shenzhen Stock Exchange Business Rules, etc. prescribed situation
- Information on shares with restricted voting rights According to Section 1 of the Securities Law
The provisions of Article 63, Yes□ No√ Whether it exists or not cannot be exercised voting shares
Further explanation for shareholders who increase their shareholdings by more than 30% ((if applicable)) Not applicable
Prepare documents for future reference
"Letter of Notification of Shareholding Reduction Progress" issued by Xinzhong Kangcheng and Xinzhong Longcheng;
Other documents required by Shenzhen Stock Exchange. Note 1: The company’s total share capital is 1,837,283,628 shares.
Announcement is hereby made.
Board of Directors of Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd. July 2, 2026